TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Erectile Function (EF) Domain of the IIEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of micro-RNA Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in numbness from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Sheehan Disability Scale (SDS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants Who Survived to 100-Days Post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Survived to One Year Post-Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Experienced Treatment-Related Mortality Within the First 100 Days
Endpoint domain: Mortality/survival
Primary endpoint: Vital signs (blood pressure, pulse rate, weight, oral body temperature)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical laboratory safety evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flap perfusion viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-Operative Pain Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Surgical Site Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Progression of left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-stent Late Lumen Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of circulating sFlt1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of vasopressor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pulmonary Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of Myoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Q-IPAVA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pulse Wave Velocity carotid-femoral (PWV-CF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse Wave Velocity carotid-femoral (PWV-CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distensibility Coefficient (DC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Advanced Glycation End products (AGEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seizure frequency per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of patients with RNA-HCV negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: anti-Xa and IIa activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Frequency of Hot Flashes After 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Severity Score of Hot Flashes After 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Severity Score of Hot Flashes After 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUVR of 18F-AV-1451
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acceptability of the optimized birthing position
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change of trough seated diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal Change in NRS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration vs. time curve (AUC) of sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage of patients with new stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in Functional Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of thoracoscopy and CT-guided pleural needle biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of thoracoscopy and CT-guided pleural needle biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with caesarean section or instrumental delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Accuracy and speed of reading individual words aloud
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients discharged earlier
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response to ziprasidone or placebo measured by CAPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to ziprasidone or placebo measured by TOP-8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in carotenoids in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in carotenoids in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Laboratory Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Examination Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Knowledge of Interprofessional Care and Practice Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Interprofessional Learning Readiness Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total Scores of Patient Perceived Quality of Care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cmax of zabofloxacin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of zabofloxacin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in performance on fMRI simulated driving Gap Acceptance Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in performance on fMRI simulated driving Road Tracking Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in performance on fMRI simulated driving Car Following Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in concentration of THC/metabolites in oral fluid tested using Draeger Drug Detection Kits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in concentration of THC/metabolites in oral fluid tested using Quantisal Oral Fluid Collection devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fractional hypoxic volume of the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in regional cerebral oxygen saturation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Conjunctival Hyperaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Limbal Hyperaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Corneal Vascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Microcysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Conjunctival Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Papillary Conjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Late loss of side branch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total distribution volume (VT) of [11C]-Lu AF88434
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(PET) of Lu AF88434
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC(0-inf)) of Lu AF88434
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Lu AF88434
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Chlamydia pneumonia and Mycoplasma pneumonia antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Death at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in oxygenated hemoglobin (Δ[HbO2])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in deoxygenated hemoglobin (Δ[Hb])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MMR Rate at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of plasma clearance of chylomicrons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to quality indicators
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Bone Shape
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Survival at 1 Year Post-CTTI
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of pyelonephritis
Endpoint domain: Adverse events/effects
Primary endpoint: Small bowel mucosal density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serologic markers of celiac disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive processing assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: pharmacokinetic profile in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacodynamic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of dronedarone and its metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of a Major Adverse Cardiovascular Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC of Celecoxib on Combination Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Celecoxib on Celecoxib Monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Equivalents (METs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of optimally deployed stents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Length of the ascending aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment-related Toxicity Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Hematology test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: margin-free (R0) resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient-reported body pain score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in 24-hour Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neural activity in attentional-related brain areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Structural changes after receiving anodal tDCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increased attentional and working memory capacity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of acute pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gingival display
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global score of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intra-uterine death
Endpoint domain: Mortality/survival
Primary endpoint: Small of gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placental abruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Maximum tolerated dose of obatoclax mesylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in large artery elasticity (LAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in small artery elasticity (SAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flow mediated vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax - the Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax - the Time of Occurrence of Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lipid profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of CD123/BDCA-2 expressing cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time To Reach The Maximum Observed Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) From Time of Administration up to 24 Hours Post Dosing (AUC24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrioventricular (AV) Synchrony During Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to significant pain relief
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of surviving patients until HSCT
Endpoint domain: Mortality/survival
Primary endpoint: Preeclampsia diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Small for gestational age at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Subjective Injection Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borg scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in QTc intervals on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in QTc intervals on Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of neuropsychiatric and CNS toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Colorectal Cancer Screening Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Day 0 to Day 84 (AUC0-84day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Self reported recidivism (arrests and undetected offenses)
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported Substance Use and Dependence - TCU
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported HIV risk behaviors (sex and IDU) - TCU
Endpoint domain: Adverse events/effects
Primary endpoint: All cause in-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Intra- and postoperative device-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: methacholine PC20 dose shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intestinal transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Thyroid stimulating hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Maintaining Average Haemoglobin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression to liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Overall response in MDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects receiving convalescent plasma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ADC measurements of metabolites within the ischemic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of MDRGNB in ICU
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Best Corrected Visual Acuity (BCVA) Total Letters Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sexual Satisfaction Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Residual antral volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Arterial partial pressure of carbon dioxide (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient expectations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SRS 22
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical Activity Behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Urinary catheter day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Post-Traumatic Stress Questionnaire-Military (PCL-M) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Center for Epidemiological Studies-Depression Scale (CES-D) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Visual Analogue Scale of Pain (VAS-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Drug Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of hospitalization or discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Average costs during the diagnosis of patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Autism Knowledge Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child Behaviour Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vineland-II, Rosenburg Self-Esteem Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting Stress Index
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Visual analogue scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in SNOT-22
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Morbidity including unexpected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Limbs With a Continued Absence of Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Limbs With a Device-related Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Response for Dysmenorrhea at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes